FDA Postmarketing Strategy Draws On 1980 Melmon Commission Report
Executive Summary
FDA's postmarketing safety agenda in 2002 derives in large part from the 20-year-old report of a pharmaceutical industry commission formed at the behest of Sen. Edward Kennedy (D-Mass.)
You may also be interested in...
Drug Risk Assessment Needs IoM Report To Synthesize Research – CERTs
The Institute of Medicine should study the current state of pharmaceutical risk assessment and recommend methodological and research improvements, participants in a Centers for Education & Research on Therapeutics risk assessment workshop suggested
Drug Risk Assessment Needs IoM Report To Synthesize Research – CERTs
The Institute of Medicine should study the current state of pharmaceutical risk assessment and recommend methodological and research improvements, participants in a Centers for Education & Research on Therapeutics risk assessment workshop suggested
Kenneth Melmon
Stanford Professor of Medicine emeritus Kenneth Melmon, MD, died April 8. Melmon chaired a commission on drug safety in the 1970s formed by the pharmaceutical industry at the behest of Sen. Edward Kennedy (D-Mass.) and was a member of FDA's new risk management advisory committee (1"The Pink Sheet" Feb. 25, p. 28)...